We at Wheeler Bio, Inc. are excited to announce our upcoming #webinar: "Modular CMC Development for Antibodies: Deploying a Purpose-Designed Path to Clinic" live on Xtalks Oct. 7th at 1pm ET! Register now to hear from our expert panel and get a detailed look at how Wheeler is changing the #CMC #development paradigm by aligning all priorities with program success through modular work packages, structured documentation support, as well as built-in accommodations and tools to support clients and the consultants that facilitate their CMC path. Plus, all attendees will gain access to an exclusive survey report with insights and data pertinent to those on the #preclinical and early #clinical #biologics pathway. Don't miss out! Follow the link below to learn more.
Wheeler Bio, Inc.
Biotechnology
Oklahoma City, Oklahoma 5,122 followers
CMC Made for Biotechs
About us
Wheeler Bio is a pioneering Contract Development and Manufacturing Organization (CDMO) focused on accelerating the discovery-to-development process for biopharmaceutical companies. Through a unique partnering model, we aim to address industry bottlenecks by facilitating smoother transitions between discovery and development phases, empowering innovators to bring novel antibody and antibody-like therapeutics to market with precision, speed, and optimized cost without ever compromising quality. Wheeler Bio specializes in mammalian cell line and process development, GLP Tox material supply, and CGMP clinical supply, leveraging our Portable CMC® platform to streamline the pathway from innovation to clinical trials. Our approach has been purposefully designed to reduce lifecycle challenges, enhance efficiency, and foster lasting collaborations within the biopharma industry.
- Website
-
https://www.wheelerbio.com/
External link for Wheeler Bio, Inc.
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Oklahoma City, Oklahoma
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Cell Line Development, Process Development, Analytical Development, Tech Transfer, CMC, Process Characterization, Formulation Development, GMP Manufacturing, Pharmaceutical Manufacturing, Clinical Manufacturing, Contract Manufacturing, Biotechnology, Pharmaceuticals, Biologics, Cell Banking , Drug Substance, Life Science, Monoclonal Antibodies, Antibody Development, and Therapeutic Development
Locations
-
Primary
120 Robert S Kerr Ave
Oklahoma City, Oklahoma 73102, US
-
655 Research Parkway
Suite 383
Oklahoma City, OK 73104, US
-
275 2nd Avenue
Waltham, MA 02451, US
Employees at Wheeler Bio, Inc.
Updates
-
Come see us at BPI! The Wheeler Bio, Inc. team will be in Boston September 23rd - 26th for the 2024 BioProcess International conference. Stop by Booth 833 to meet with Stewart McNaull, Ken Meek, and Peter Rock to learn about our turnkey #antibody platform (Portable CMC®), our #domestic small batch #biologics manufacturing solutions, and how we are supporting the #ADC supply chain by providing intermediate manufacturing to innovators. Also, don't forget to attend Stewart's talk entitled "Deploying Purpose-Built CMC Development Modules for Predictability and Speed to IND" on September 25th at 2:50pm EDT! We can't wait to see you all in Boston! Reach out to schedule a meeting: https://lnkd.in/e2ZpBWJN
-
We are honored to share that Wheeler Bio, Inc.'s own Jesse McCool has received the Building Better Regions Superstar Award for his contributions to the Oklahoma Biotech Innovation Cluster! Through his work developing the OU Bioprocessing Core Facility as part of the Build Back Better Regional Challenge grant, Jesse's contributions to developing the bioprocessing workforce in Oklahoma lays the foundation for growth in the industry and provides opportunities for the next generation of Oklahomans. Please join us in congratulating Jesse for this achievement! #Biotech #Workforce #BBBRC #Bioprocessing #EconomicDevelopment
-
Wheeler Bio, Inc. reposted this
Come listen to my colleagues at Wheeler Bio, Inc. share their insights on the CMC development process and how proper alignment can lead to a streamline the path to clinic approach! #CMC #development #biologics
We at Wheeler Bio, Inc. are excited to announce our upcoming #webinar: "Modular CMC Development for Antibodies: Deploying a Purpose-Designed Path to Clinic" live on Xtalks Oct. 7th at 1pm ET! Register now to hear from our expert panel and get a detailed look at how Wheeler is changing the #CMC #development paradigm by aligning all priorities with program success through modular work packages, structured documentation support, as well as built-in accommodations and tools to support clients and the consultants that facilitate their CMC path. Plus, all attendees will gain access to an exclusive survey report with insights and data pertinent to those on the #preclinical and early #clinical #biologics pathway. Don't miss out! Follow the link below to learn more.
Modular CMC Development for Antibodies: Deploying a Purpose-Designed Path to Clinic
xtalks.com
-
On the 23rd anniversary of the deadliest terror attack in U.S. history, we remember and pay our respects to the thousands of innocent civilians whose lives were taken, the hundreds of courageous first-responders that sacrificed everything to save their fellow citizens, and the families forever changed by this atrocity. While today serves as a painful reminder of the events that unfolded in 2001, we must work to shift our focus to celebrate the bravery, selflessness, and the indominable spirit of the heroes that were born from the chaos of 9/11. Just as the nation was brought together on 9/12/2001 through this tragedy, we hope that we can similarly set our differences aside and come together by remembering what binds us, instead of what separates us. #NeverForget
-
Since the #BIOSECURE Act was introduced in the U.S. House of Representatives at the beginning of this year, the speculation and concern over its potential impacts have sent shockwaves through the #biopharma industry. With emerging #biotechs comprising 80% of the investigational drug pipeline, 65% of these companies working with overseas #CDMOs, and 80% of all APIs consumed in the U.S. being manufactured overseas, the concerns surrounding the impact this may have on drug development and supply as a whole are apparent. These concerns highlight the dire necessity to not only build up #domestic manufacturing capacity in order to mitigate against potential drug shortages, as was seen in the first half of 2024, but also the imperative for emerging biotechs to reshore their manufacturing before potentially losing out on federal funding, threatening life-saving drug programs. In our latest blog, we take a look at the potential impacts of the BIOSECURE Act on emerging biotechs, the advantages of prioritizing domestic biologics manufacturing, and how this could particularly threaten access to small-scale production. To learn more about how Wheeler Bio, Inc. is deploying our purpose-built Portable CMC® platform to ameliorate these concerns and provide a rapid, flexible, and cost-effective path to the clinic, visit wheelerbio.com or reach out any time to [email protected] to speak with our team!
Why Reshoring Small Batch Pharma Production is Critical for Biotechs - Wheeler Bio
https://wheelerbio.com
-
Congratulations to the New England Free Jacks® on their second, back-to-back MLR championship! We at Wheeler Bio, Inc. are proud to have been part of the Free Jacks' 2024 championship pursuit as sponsors but also as fans. The character, resilience, and commitment to excellence displayed by the team was inspiring to all that watched. We cannot wait to see what next season has in store as the sport continues to grow!
Free Jacks Win 2024 MLR Championship For Second Consecutive Year
https://freejacks.com
-
𝐖𝐡𝐲 𝐝𝐨𝐞𝐬 𝐭𝐡𝐞 𝐜𝐨𝐧𝐯𝐞𝐧𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐃𝐌𝐎 𝐦𝐨𝐝𝐞𝐥 𝐧𝐞𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐫𝐞𝐛𝐮𝐢𝐥𝐭? There is a fundamental mismatch between the needs of drug innovators and the services provided by conventional CDMOs. This ingrained misalignment is what led to the conception of Wheeler Bio, Inc. Considering venture-backed biotechs account for around 80% of all programs in the investigational drug pipeline, these companies require CDMO services that are flexible, efficient, and align with their goals for the success of their programs. At Wheeler, we recognized the scarcity of these attributes in the CDMO industry and the impact this has on the overall therapeutic pipeline. In order to solve these needs and thereby ensure more advanced therapeutics reach patients in need, we rebuilt the conventional CDMO model in favor of innovators through: ▶ 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐞𝐝 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐦𝐨𝐝𝐞𝐥: Uniting specialists into a one-stop-shop, ameliorating the CRO-CDMO trench and building a clear path from Discovery to IND. ▶ 𝐌𝐨𝐝𝐮𝐥𝐚𝐫 𝐰𝐨𝐫𝐤 𝐩𝐚𝐜𝐤𝐚𝐠𝐞𝐬: Low-cost entry, no scope creep, access to early CMC data, and unmatched flexibility. ▶ 𝐓𝐮𝐫𝐧𝐤𝐞𝐲 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦: Greater speed, reduced risk, enhanced predictability, and an intense focus on antibody and antibody-like modalities. ▶ 𝐏𝐮𝐫𝐩𝐨𝐬𝐞 𝐛𝐮𝐢𝐥𝐭 𝐟𝐚𝐜𝐢𝐥𝐢𝐭𝐢𝐞𝐬: Right scale manufacturing, flexible ballroom suites, and state-of-the-art technologies. ▶ 𝐀𝐥𝐥-𝐢𝐧-𝐨𝐧𝐞 𝐩𝐫𝐢𝐜𝐢𝐧𝐠: Predictable cash burn, no surprise costs or budget creep. Check out our latest article below and reach out to [email protected] to learn more about how we are changing the CDMO paradigm! #Biotech #Biopharma #Antibody #Therapeutics
Rethinking the Conventional CDMO Model - Wheeler Bio
wheelerbio.com
-
ICYMI: Wheeler Bio, Inc.'s CEO and Co-Founder Jesse McCool joined a panel with our partners at Charles River Laboratories to discuss how our integrated partnership model is streamlining the path to IND by uniting specialists in their respective fields into a one-stop-shop from early discovery to FiH. Check out the video to learn more about how Wheeler is applying our purpose-built CMC development and right-size manufacturing platform (Portable CMC®) to solve translational challenges for early-stage biotechs! #CMC #Pharma #Biologics #Antibody #Therapeutics
Learn more about how the partnership of Charles River and Wheeler Bio, Inc. marries cutting-edge technology, specialized expertise, and an unmatched continuous experience for taking antibody-based therapies from discovery to first-in-human clinical trials: https://okt.to/1V3png #advancetherapies #monoclonalantibody #biomanufacturing #biologics #mabs
-
Wheeler Bio, Inc. reposted this
At Wheeler Bio, Inc., we are bringing the hub-and-spoke model to the CDMO space to solve longstanding obstacles for early biotechs! Innovators are faced with ample challenges from the start due to limited resources, high burn rates, and an uncertain funding environment. Due to this, it becomes difficult to manage multiple vendors, tech transfers, and high upfront costs. The Wheeler hub-and-spoke model connects the best in their respective fields into one streamlined offering, ensuring your program receives the specialized knowledge and experience it requires while integrating into a one-stop-shop from Discovery to IND. Follow the link below to learn more about how we are changing the CDMO landscape to cater to early stage biotechs or feel free to reach out to [email protected] to chat with us! #Biotech #Biologics #Pharma #CMC #StartUp
CDMO Vision - Pushing the Boundaries - Wheeler Bio
https://wheelerbio.com